Genomic Health Announces Initial Public Offering

REDWOOD CITY, Calif., Sept. 28, 2005 /PRNewswire-FirstCall/ -- Genomic Health, Inc. today announced the pricing of its initial public offering of 5,016,722 shares of its Common Stock at $12.00 per share. J.P. Morgan Securities Inc. and Lehman Brothers Inc. acted as joint book-running managers for this offering, and Piper Jaffray & Co., Thomas Weisel Partners LLC and JMP Securities LLC acted as co-managers.

All of the shares were sold by the Company. The Company has granted the underwriters an option to purchase an additional 752,508 shares to cover over- allotments, if any. Genomic Health's Common Stock will be traded on the Nasdaq National Market beginning September 29, 2005 under the symbol "GHDX." The offering is expected to close on October 4, 2005, subject to customary closing conditions.

A Prospectus relating to these securities may be obtained from J.P. Morgan Securities Inc., Prospectus Department, One Chase Manhattan Plaza, New York, NY 10081, telephone (212) 552-5164, or from Lehman Brothers Inc., c/o ADP Financial Services, Prospectus Fulfillment, 1155 Long Island Avenue, Edgewood, NY 11717 or by fax at (631) 254-7268 or email request to sabrina_neat@adp.com or monica_castillo@adp.com.

About Genomic Health

Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions.

Source: Genomic Health, Inc.

Contact Information

For Investors:
650.569.2281
investors@genomichealth.com

For Media:
650.569.2215
media@genomichealth.com

  

Email Alerts

To sign-up to receive email alerts for press releases, stock information, new calendar events and/or SEC filings click here.

 

Shareholder Tools

  

DISCLAIMER

The information in the press releases should be considered accurate only as of the date of the document or presentation. We disclaim any obligation to supplement or update the information in these documents or presentations.


Forward-Looking Statements

This website contains forward-looking statements. Any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including risks and uncertainties associated with the reimbursement for and adoption of Oncotype DX; commercialization of any future tests; the nature and sources of our revenues; our dependence on collaborative relationships; the regulation of Oncotype DX or any future tests we may develop by the FDA; the attributes of our products; the benefits of personalized medicine and its ability to impact treatment decisions; the outcome and success of clinical trials; the applicability of clinical results to actual outcomes; the company's beliefs regarding the potential benefits that may be obtained from additional tests; and other factors detailed from time to time in Genomic Health's periodic filings with the Securities and Exchange Commission. Genomic Health, Inc. specifically disclaims any obligation to update any forward-looking statements.